The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Manufacturer Inmar has initiated a recall as a precautionary measure involving Dabigatran Etexilate Mesylate Capsules 75 mg and 150 mg, lot number{s} 22142448, 22142449, 22142450, 22143845, 22142462, 22142463, 22142464, 22143000, 22143001, and 22143002. This recall should be conducted to the retail level (Class II). This recall is being made with the knowledge of the Food and Drug Administration.

Product Name	Lot Number	r Strength	Expiration Date	Pack Size	NDC	Initial Distribution	Quantity Distributed
						Date	
Dabigatran Etexilate				HDPE			
	22142448	150mg	May 2024	Bottle 60	6787747560	8-22-2022	2801
Mesylate Dabigatran				Caps HDPE			
Etexilate	22142449	150 mg	May 2024	Bottle 60	6787747560	8-22-2022	2937
Mesylate				Caps			
Dabigatran Etexilate Mesylate				HDPE			
	22142450	150 mg	May 2024	Bottle 60	6787747560	8-23-2022	3565
				Caps			
Dabigatran Etexilate				HDPE			
	22143845	150 mg	July 2024	Bottle 60	6787747560	10-24-2022	3501
Mesylate Dabigatran				Caps HDPE			
Etexilate  Mesylate	22142462	75 mg	May 2024	HDFL	6787747460	6-29-2022	2112
				Bottle 60 Caps	0707747400	0 23 2022	2112
Dabigatran Etexilate				HDPE			
	22142463	75 mg	May 2024	D - ++  - CO	6787747460	6-29-2-22	2208
Mesylate Dabigatran Etexilate			·	Bottle 60 Caps			
				HDPE			
	22142464	75 mg	May 2024	Bottle 60	6787747460	6-29-2022	2208
Mesylate				Caps			
Dabigatran Etexilate	22143000	75 mg	June 2024	HDPE	6787747460	8-22-2022	2280

Mesylate				Bottle 60 Caps			
Dabigatran Etexilate				HDPE			
	22143001	75 mg	June 2024	Bottle 60	6787747460	8-23-2022	2376
Mesylate				Caps			
Dabigatran Etexilate				HDPE			
	22143002	75 mg	June 2024	Bottle 60	6787747460	8-26-2022	2376
Mesylate				Caps			